1
EDITORIAL
Potentials and limitations of current and emerging immunotherapies
Uwe K. Zettl and Eilhard Mix
2-6
Pathophysiology of multiple sclerosis
Thomas Korn
7-14
Animal models of multiple sclerosis for the development and validation of novel therapies – potential and limitations
Eilhard Mix, Hans Meyer-Rienecker and Uwe K. Zettl
15-21
Immunomodulatory treatment strategies in multiple sclerosis
Bernd C. Kieseier, Heinz Wiendl, Verena I. Leussink and Olaf Stüve
22-27
Immunosuppression in clinical practice
Approaches to individualized therapy
Andrew Chan, Olaf Stüve and Nicolas von Ahsen
28-35
Monoclonal antibodies in the therapy of multiple sclerosis
An overview
P. S. Rommer, O. Stüve, R. Goertsches, E. Mix and U. K. Zettl
36-42
Corticosteroids and plasma exchange in multiple sclerosis
Hayretin Tumani
43-47
Stem cell transplantation in multiple sclerosis
Sven Schippling, Christoph Heesen, Axel Zander and Roland Martin
48-57
Monitoring of multiple sclerosis immunotherapy
From single candidates to biomarker networks
Robert H. Goertsches, Michael Hecker and Uwe K. Zettl
58-65
α4-Integrin antagonism with natalizumab
Effects and adverse effects
Olaf Stüve, Ralf Gold, Andrew Chan, Eilhard Mix and Uwe Zettl, et al.
66-68
Clinical trials in multiple sclerosis: Current and future requirements – potential pitfalls
P. Rieckmann
69-76
Isolated, relapsing and progressive demyelinating diseases of the central nervous system
Axel Petzold
77-81
Neuroprotection and neuroregeneration in multiple sclerosis
Martin Stangel
82-86
Complementary and alternative medicine in multiple sclerosis
Annett Apel-Neu and U. K. Zettl
87-92
Compliance, adherence, and the treatment of multiple sclerosis
Thomas Klauer and Uwe K. Zettl
93-96
Recent clinical trials and future therapies
Sven G. Meuth, Christoph Kleinschnitz and Heinz Wiendl
97-101
What can we learn from failed clinical trials in multiple sclerosis?
Tjalf Ziemssen
102-108
National MS registries
Peter Flachenecker and Kristin Stuke
109-114
Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy
Alexander Winkelmann, Robert Patejdl, Sabine Wagner, Reiner Benecke and Uwe Klaus Zettl
115-118
Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosis
Robert Patejdl, Alexander Winkelmann, Reiner Benecke and Uwe Klaus Zettl
119-122
Paediatric multiple sclerosis: The experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence
Wiebke Stark*, Peter Huppke* and Jutta Gärtner
123-126
Diagnostic algorithm for the differentiation of leukodystrophies in early MS
Wolfgang Köhler